Adrenocortical carcinoma natural history: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{RT}} {{AAM}} | {{CMG}} {{AE}} {{RT}} {{AAM}} | ||
==Overview== | ==Overview== | ||
Prognosis is generally poor, and the 5-year survival rate of patients with adrenocortical carcinoma [[Cancer staging|stage]] I-III is approximately 30%. | Prognosis is generally poor, and the 5-year survival rate of patients with adrenocortical carcinoma [[Cancer staging|stage]] I-III is approximately 30%. Complication may include [[metastasis]], [[Conn syndrom]] and [[Cushing syndrom]] | ||
==Complications== | ==Complications== | ||
The following are the complications of [[Adrenocortical carcinoma]]: | The following are the complications of [[Adrenocortical carcinoma]]: | ||
| Line 10: | Line 9: | ||
* [[Conn syndrome]] | * [[Conn syndrome]] | ||
* [[Hypertension]] | * [[Hypertension]] | ||
* Local and distant [[metastasis]] | |||
* Local and | |||
* [[Paraneoplastic syndrome]] | * [[Paraneoplastic syndrome]] | ||
* Tumor [[thrombus]] formation | * Tumor [[thrombus]] formation | ||
| Line 18: | Line 15: | ||
==Prognosis== | ==Prognosis== | ||
Adrenocortical carcinoma, generally, carries a poor prognosis.<ref name=allolio>{{cite journal | author = Allolio B, Fassnacht M | title = Clinical review: Adrenocortical carcinoma: clinical update. | journal = J Clin Endocrinol Metab | volume = 91 | issue = 6 | pages = 2027-37 | year = 2006 | id = PMID 16551738}} [http://jcem.endojournals.org/cgi/content/full/91/6/2027 Free Full Text].</ref> | Adrenocortical carcinoma, generally, carries a poor prognosis.<ref name=allolio>{{cite journal | author = Allolio B, Fassnacht M | title = Clinical review: Adrenocortical carcinoma: clinical update. | journal = J Clin Endocrinol Metab | volume = 91 | issue = 6 | pages = 2027-37 | year = 2006 | id = PMID 16551738}} [http://jcem.endojournals.org/cgi/content/full/91/6/2027 Free Full Text].</ref> | ||
The five-year disease-free survival rate for a complete resection of a [[Cancer staging|stage]] I-III is approximately 30%.<ref name=allolio/> | |||
The most important prognostic factors are: | The most important prognostic factors are: | ||
* Age of the patient | * Age of the patient | ||
* Stage of the tumor | * Stage of the tumor | ||
* Mitotic activity | * Mitotic activity | ||
* Venous invasion | * Venous invasion | ||
Revision as of 21:50, 27 August 2015
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma natural history On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma natural history |
|
Risk calculators and risk factors for Adrenocortical carcinoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3]
Overview
Prognosis is generally poor, and the 5-year survival rate of patients with adrenocortical carcinoma stage I-III is approximately 30%. Complication may include metastasis, Conn syndrom and Cushing syndrom
Complications
The following are the complications of Adrenocortical carcinoma:
- Cushing's syndrome
- Conn syndrome
- Hypertension
- Local and distant metastasis
- Paraneoplastic syndrome
- Tumor thrombus formation
Prognosis
Adrenocortical carcinoma, generally, carries a poor prognosis.[1] The five-year disease-free survival rate for a complete resection of a stage I-III is approximately 30%.[1]
The most important prognostic factors are:
- Age of the patient
- Stage of the tumor
- Mitotic activity
- Venous invasion
- Weight more than 50 Kg
- Diameter more than 6.5 cm
- Ki-67/MIB1 labeling index
References
- ↑ 1.0 1.1 Allolio B, Fassnacht M (2006). "Clinical review: Adrenocortical carcinoma: clinical update". J Clin Endocrinol Metab. 91 (6): 2027–37. PMID 16551738. Free Full Text.